A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer

Archives of Gynecology and Obstetrics

Volumn 269, Issue 4, 2004, Pages 263-265

  Rossi, Angela Cristina ^a   Di Vagno, Giovanni ^a   Cormio, Gennaro ^a   Cazzolla, Ambrogio ^a   Stefanelli, Sergio ^a   D'Elia, Emanuela ^a   Selvaggi, Luigi ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

CA 125; Ovarian carcinoma; Prognostic factors

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CANCER; PREOPERATIVE EVALUATION; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY;

EID: 2442663901     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-002-0404-6     Document Type: Article

References (19)

1. Canney PA, Moore M, Wilkinson PM, James RD (1984) Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50:765-769
2. Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA 125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227-231
3. Cooper BC, Sood AK, David CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE (2000) Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100:59-64
4. Frasci G, Conforti S, Zullo F et al (1983) A risk model for ovarian cancer patients using Ca 125. Time to normalization renders second look laparotomy redundant. Cancer 77:1122
5. Green JA, Berns E, Hensen-Logmans S, Van der Burg ME, Van Dam PA, Van Diest P, Vergote I (1999) Biological markers in ovarian cancer-implications for clinical practice. CME J Gynecol Oncol 4:13-21
6. Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yammamoto K, Nagata I (1999) Preoperative determination of several serum tumor markers in patients with epithelial ovarian carcinoma. Gynecol Oncol Invest 47:52-57
7. Laframboise S, Nedelcu R, Murphy J, Cole DEC, Rosen B (2002) Use of CA 125 and ultrasound in high-risk women. Int J Gynecol Cancer 12:86-91
8. Leitao M, Boyd J (2002) Preoperative CA 125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma. Gynecol Oncol 84:413-415
9. Maggino T, Gadducci A (2000) Serum markers as prognostic factors in epithelial ovarian cancer; an overview. Eur J Gynecol Oncol 21:64-69
10. Makar AP (1993) Serum CA 125 level allows early identification of non responders during induction chemotherapy. Gynecol Oncol 49:73-79
11. Makar AP, Baekelandt MD, Tropè C et al (1995) The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175
12. Mogensen O (1992) Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 44:207-212
13. Nagele E, Petru E, Medl M et al (1995) Preoperative CA 125; an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 86:259
14. Petignat P, Joris F, Obrist R (2000) How CA 125 is used in routine clinical practice. Eur J Cancer 36:1933-1937
15. Pickel H (1999) Prognostic factors in ovarian cancer. CME J Gynecol Oncol 4:8-12
16. Tuxen MK, Solertormost G, Dombernowsky P (1995) Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21:215-245
17. Vergote IB, Bormer OP, Abeler VM (1987) Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 157:88-92
18. Vergote IB, Abeler VM, Bormer OP et al (1992) CA 125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian cancer. Tumor Biol 13:168-174
19. Young RC, Walton L, Ellenberg SS et al (1990) Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021